Vaccines - Suriname

Suriname

The Vaccines market in Suriname is expected to witness significant growth in the coming years.
By 2024, the revenue in this market is projected to reach US$2.50m.
Moreover, the market is expected to exhibit a promising annual growth rate (CAGR 2024-2029) of 0.94%, leading to a market volume of US$2.62m by 2029.
When compared globally, United States is anticipated to generate the highest revenue in the Vaccines market, amounting to US$29,120.00m in 2024.
As a journalist with deep knowledge about history, facts, and insights, I can provide you with a country-specific statement about current trends in the vaccine market in Suriname: "Suriname, a developing nation in South America, is witnessing an increasing demand for vaccines to combat various diseases and improve public health."

Key regions: Australia, Italy, France, South Korea, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

Suriname, a small country in South America, has been experiencing a growing demand for vaccines in recent years.

Customer preferences: The population of Suriname has been increasingly aware of the importance of vaccination in preventing diseases. This has led to a higher demand for vaccines, both for children and adults. Additionally, the government of Suriname has been promoting vaccination campaigns, which has also contributed to the growing demand.

Trends in the market: One of the main trends in the vaccines market in Suriname is the increasing demand for vaccines against infectious diseases such as measles, rubella, and hepatitis B. This trend is in line with the global trend towards preventing infectious diseases through vaccination. Another trend in the market is the growing demand for vaccines for adults, especially for travelers and those working in high-risk environments.

Local special circumstances: Suriname has a diverse population, with different ethnic groups and cultures. This has led to a demand for vaccines that are tailored to specific cultural and religious practices. For example, some vaccines may not be acceptable to certain religious groups, and alternative vaccines may need to be provided.

Underlying macroeconomic factors: Suriname has been experiencing economic growth in recent years, which has contributed to the growing demand for vaccines. The government has also been investing in healthcare infrastructure, which has made vaccines more accessible to the population. However, the country still faces challenges in terms of healthcare access and quality, which may affect the availability and affordability of vaccines in some areas.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.